Las Vegas, NV -- (SBWIRE) -- 12/20/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more .EquityObserver.com issues a special report on the following stocks: Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB), Oclaro, Inc. (NASDAQ:OCLR), Cinedigm Corp (NASDAQ:CIDM), Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)
Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) managed to keep its fall at -0.91% on above-normal volume of 2.17M shares. The stock settled at $2.17 after floating in a range of $2.15 to $2.25. Its latest price has reached market capitalization of $291.53 million. Its 52-week range has been $1.11 to $3.59. Navidea Biopharmaceuticals, Inc. (Navidea), formerly Neoprobe Corporation, is a biopharmaceutical company focused on the development and commercialization of precision diagnostic agents. As of December 31, 2011, the Company’s radiopharmaceutical development programs included Lymphoseek (Lymphoseeks.
Has NAVB Found The Bottom and Ready To Move Up? Find Out Here
Oclaro, Inc. (NASDAQ:OCLR) traded up on a volume of 1.97 million, higher than its standard daily volume. Shares have gained 0.48% to $2.09. Over the last twelve months, the stock has gained 19.43% and faced a worst price of $0.88. Oclaro, Inc. is a provider of optical communications and laser components, modules and subsystems for a range of markets, including telecommunications (telecom), industrial, scientific, consumer electronics and medical.
For How Long OCLR’s Gloss will Attract Investors? Find out via this report
Cinedigm Corp (NASDAQ:CIDM) settled -1.86% lower at $2.11 on above-normal volume of 1.90M shares during the last trading day. The stock has its 12-month high at $2.45 and 52-week low price was $1.5. It traded in a range of $1.98 to $2.17 during the last trading day. Cinedigm Corp., formerly Cinedigm Digital Cinema Corp. (Cinedigm) is a digital cinema services, software and content marketing and distribution company supporting and capitalizing on the conversion of the exhibition industry from film to digital technology.
Will CIDM Get Buyers Even After The Recent Rally? Find Out Here
In the last trading session, Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) was up on high volume, trading at a volume of 1.89M versus its average daily volume of 862,248.00 shares. At $2.42, the stock has attained market capitalization of 211.58 million. Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company. The Company discovers and develops small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Its research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms.
Will RIGL Continue To Move Higher? Find Out Here
About Equity Observer
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/
Employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimer at: http://www.equityobserver.com/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)